MedTrace Logo

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

NCT03153293 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2020-09-17

No results posted yet for this study

Summary

This study is meant to evaluate the safety and efficacy of rAAV2-ND4 treatment for Leber hereditary optic neuropathy with the G11778A mutation in mitochondrial DNA.

Conditions

  • Leber Hereditary Optic Neuropathy

Interventions

DRUG

rAAV2-ND4

a Single IVT Injection

Sponsors & Collaborators

  • Taihe Hospital

    collaborator OTHER

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Bin Li, PhD,MD · Deputy Director of Ophthalmology,Tongji Hospital

  • Yong Zhang, PhD,MD · Director of Ophthalmology，Shiyan Taihe Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-27
Primary Completion
2020-01-15
Completion
2025-01-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03153293 on ClinicalTrials.gov